Genes matter while treating breast cancer.
What is it about?
This publication explores the relationship of a set of genotypes of drug metabolizing enzymes to plasma clearance as well as most common adverse effect of a commonly used cytotoxic and immunosuppressive drug cyclophosphamide. It supports involvement of CYP2C19, ALDH3A1 and GSTA1 in this regard.
Why is it important?
This article explores the genetic basis of variation in breast cancer treatment.
The following have contributed to this page: Dr Nasir Ali Afsar
In partnership with: